Poonawalla wished the country and Prime Minister Narendra Modi success for the vaccination programme.
The Serum Institute of India has stockpiled 40 mn-50 mn doses and is adding more every week. Most of these will come to India.
'People are already sending congratulatory messages. But I have said, "Please don't until the trials are over".'
Covishield vaccine production won't be hit due to the fire, Serum Institute of India Chief Executive Officer Adar Poonawalla said. The Manjari facility is where the Covishield vaccine used in the nationwide inoculation drive against the pandemic is made.
Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday said it has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection.
Poonawalla, during an interaction with Odisha Chief Minister Naveen Patnaik through a video conference, expressed optimism that the COVID-19 vaccine could be ready by October-November this year and the next phase of the trial can start in mid-August in India. According to a press note released by the CMO, Poonawalla has informed that the Oxford University vaccine has shown promising results in the first phase trial.
In a joint statement posted on their respective twitter accounts, the companies said Serum Institute Chief Executive Officer Adar Poonawalla and Bharat Biotech Chairman Krishna Ella communicated their combined intent to develop, manufacture and supply the COVID-19 vaccines.
COVAX, 'the global COVID vaccine equity scheme', has so far delivered 65 million doses to 124 countries and economies but it is dependent on countries and manufacturers honouring their commitments.
'WHO issued an emergency use listing for Covovax, expanding the basket of WHO-validated vaccines against COVID-19. The vaccine is produced by the Serum Institute of India under licence from Novavax,' the world health body said in a tweet on Friday.
If the DCGI grants regular marketing authorisation, Covishied will be the second vaccine in the world to receive such approval.
The Covishield maker's forte throughout the past half a century has been a combination of affordable vaccines and high volumes. Its tetanus, diphtheria and measles vaccines are known throughout the world, reports Sohini Das.
By January-February, it's expected to have at least 100 million doses for the Indian government, reports Sohini Das.
The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.
Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its candidate.
Raja Ravi Varma's painting Yashoda and Krishna was recently acquired by Cyrus Poonawalla and his son, the vaccine manufacturer's CEO Adar Poonawalla, for Rs 167.2 crore, setting a new benchmark for modern Indian art.
Pharma tycoon Adar Poonawalla has emerged as a potential suitor for the Indian Premier League franchise Royal Challengers Bengaluru, sparking fresh speculation around a possible change in ownership of one of the league's most high-profile teams.
The Pune-based company's chief executive Adar Poonawalla said the company, which is the largest vaccine maker in the world, is putting $200 million at risk by manufacturing nearly 300 million doses before the final nod to launch the vaccine in market, which is expected at best by the end of the year.
It is not yet clear if Diageo Plc is looking to sell its complete stake in RCB.
Poonawalla has been getting threats from various groups regarding the COVID-19 vaccine supplies.
Poonawalla noted that reducing the timeframe would give "real relief" to the people who want to travel abroad.
'The challenge will be making sure its efficacy is high.' 'If a vaccine is only 50 to 60 per cent efficient, it's a double-edged sword.'
The Covid-19 vaccine demonstrated an overall 90.4 per cent efficacy in phase 3 clinical trials, reports Sohini Das
There are a number of trial sites across both Mumbai and Pune that we have shortlisted, as these cities have many hotspots, which will help us understand the efficacy of the vaccine, the company's chief executive Adar Poonawalla said.
'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'
One consortium is led by Manipal Hospitals' Dr Ranjan Pai along with US private equity firm KKR and Singapore investment major Temasek. The other is a combine of Swedish private equity firm EQT and Premji Invest, the investment office backed by Wipro founder Azim Premji.
The PM's visit would signal a strong intent towards making sure India becomes a beneficiary as vaccines become a massively traded commodity in the coming years.
Serum Institute of India chief Adar Poonawalla will pay 138 million (about Rs 1,444 crore) for a Mayfair mansion in London in one of the city's most expensive home sales of the year
'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'
What the UK is getting out of the Serum Institute is what India is losing. And the responsibility of the Indian State ought to have been to dictate where Serum Institute's vaccine doses should go, argues Ambassador M K Bhadrakumar.
Currently, Covishield and other COVID vaccines are approved for people above the age of 18 years.
SII executive director Suresh Jadhav on Friday alleged that the government began inoculating people from multiple age groups without taking into account the available stock of vaccines and the WHO guidelines.
The development comes after requests for indemnity and exemption from bridging trials have been made by Pfizer and Moderna to the Indian government.
Apart from making efforts to meet the requirements of India, the company is also trying its best to balance the needs of the rest of the world, he added.
Billionaire David Blitzer, co-founder of Harris Blitzer Sports & Entertainment, is conducting due diligence on Royal Challengers Bengaluru and Rajasthan Royals.
Adar Poonawalla says it took a five-minute chat with his father Cyrus before making the decision to manufacture Covishield. The bet paid off, and handsomely. Serum Institute now has the capacity to make 4 billion doses of Covishield annually.
Poonawalla was talking to media persons amid rising cases of coronavirus infections in the country since March.
'We have just scratched the surface because cricket has been around for the longest time.'
'Once DCGI will give us the permission to restart the trials in India, we will resume the trials,' Serum Institute of India (SII) said in a statement.
India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in an affordable price range of Rs 200-400, Serum Institute of India CEO Adar Poonawalla said on Thursday.
NCP president Sharad Pawar may be busy getting ready for the INDIA Opposition bloc meeting in Mumbai with other Maha Vikas Aghadi (MVA) constituents, but his close friend and industrialist Dr Cyrus Poonawalla has a piece of advice for the octogenarian leader.
